RPRX - CIK 0001802768
The table below shows Royalty Pharma plc's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B | $1.01B |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.53B |
| $1.80B |
| $1.27B |
| $2.55B |
| $2.88B |
| $2.70B |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $924.63M | - | - | - | - | - |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $636.21M | $1.25B | $161.38M | $1.17B | $171.25M | $307.89M |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B | $5.82B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B |
| Retained earnings | $2.36B | $2.85B | $2.52B | $1.96B | $2.26B | $1.92B |
| Total equity | - | - | - | - | - | - |